June 9, 2023

FDA approves first gene therapy for hemophilia B

On November 22, 2022, the FDA approved Hemgenix®, an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:

  • Currently use Factor IX (FIX) prophylaxis therapy, or
  • Have current or historical life-threatening hemorrhage, or
  • Have repeated, serious spontaneous bleed episodes

The HOC has individuals who expressed interest in Hemgenix, have completed their pre-screening eligibility and are in the final stages of meeting all the requirements needed for gene therapy The HOC medical team has participated in extensive educational trainings and are knowledgeable about all aspects of gene therapy with Hemgenix®. This includes, but is not limited to, preparation for treatment, administration of the therapy, and close monitoring once it has been given.

If you have any questions or want more information about Hemgenix®, please contact your hemophilia treatment center.

LEARN MORE ABOUT HEMGENIX®

Recent Posts

Comprehensive Care at Hemophilia Treatment Centers

Hemophilia is a complex bleeding disorder requiring specialized management to maintain a high quality of life. Hemophilia treatment centers (HTCs) offer a multidisciplinary approach to care, designed to address the diverse needs of individuals living with hemophilia...

Advanced Treatments for Von Willebrand’s Disease

Understanding Von Willebrand Disease Von Willebrand Disease (vWD) is one of the most common hereditary bleeding disorders, affecting both men and women equally. It occurs due to a deficiency or dysfunction of von Willebrand factor (vWF), a protein crucial for blood...

Finding the Right Hemophilia Treatment Center Near You

For individuals and families navigating the complexities of hemophilia and other bleeding disorder diagnoses, finding a treatment center that offers comprehensive, personalized care is paramount. This in-depth guide aims to illuminate the path to finding the right...

Glanzmann Thrombasthenia: Understanding Your Treatment Options

Glanzmann Thrombasthenia is a rare bleeding disorder that necessitates a nuanced approach to care and management. This detailed guide not only elucidates treatment strategies but also underscores the significant support network available through the Hemophilia...

Introduction to “HHT Treatment: What You Need to Know”

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is a genetic disorder that affects blood vessels and can lead to significant health issues. Understanding the current treatments for HHT is crucial for those diagnosed with the...

Understanding and Managing Von Willebrand Disease

Von Willebrand Disease (VWD) is the most common hereditary bleeding disorder, affecting both men and women. Despite its prevalence, myths and uncertainties surround its management and impact on daily life. This comprehensive guide aims to demystify VWD, offering...

Navigating Medical Treatment for Hemophilia: A Comprehensive Guide

Hemophilia, a rare but significant bleeding disorder, requires nuanced understanding and specialized care. This guide, leveraging insights from the Hemophilia Outreach Center (HOC) and current medical institutions, offers a deep dive into managing hemophilia...

Aging and Bleeding Disorders

As our bleeding disorder population’s life expectancy continues to rise to that of the average American, our patients need to understand that they are at risk for the same disease states that over 50% of all Americans now...

Social Media